Supernus to Participate in the 2025 Jefferies Global Healthcare Conference
Supernus Pharmaceuticals (NASDAQ: SUPN), a biopharmaceutical company specializing in central nervous system (CNS) diseases, announced its participation in the 2025 Jefferies Global Healthcare Conference. President and CEO Jack A. Khattar will engage in a fireside chat on June 4, 2025, at 2:00 p.m. ET in New York City.
Investors can arrange meetings with management through the Jefferies conference coordinator. The presentation will be available via live audio webcast, accessible through the company's website, with a replay available for 60 days post-conference.
Supernus Pharmaceuticals (NASDAQ: SUPN), un'azienda biofarmaceutica specializzata nelle malattie del sistema nervoso centrale (SNC), ha annunciato la sua partecipazione alla Jefferies Global Healthcare Conference 2025. Il presidente e CEO Jack A. Khattar parteciperà a una conversazione informale il 4 giugno 2025, alle 14:00 ET a New York.
Gli investitori possono organizzare incontri con il management tramite il coordinatore della conferenza Jefferies. La presentazione sarà disponibile in diretta audio streaming, accessibile tramite il sito web dell'azienda, con una replica disponibile per 60 giorni dopo la conferenza.
Supernus Pharmaceuticals (NASDAQ: SUPN), una compañía biofarmacéutica especializada en enfermedades del sistema nervioso central (SNC), anunció su participación en la Conferencia Global de Salud Jefferies 2025. El presidente y CEO Jack A. Khattar participará en una charla informal el 4 de junio de 2025 a las 2:00 p.m. ET en la ciudad de Nueva York.
Los inversores pueden coordinar reuniones con la dirección a través del coordinador de la conferencia Jefferies. La presentación estará disponible mediante una transmisión de audio en vivo, accesible a través del sitio web de la compañía, con una repetición disponible durante 60 días después de la conferencia.
Supernus Pharmaceuticals (NASDAQ: SUPN)는 중추신경계(CNS) 질환을 전문으로 하는 생명공학 제약 회사로, 2025년 Jefferies 글로벌 헬스케어 컨퍼런스에 참가한다고 발표했습니다. 사장 겸 CEO인 Jack A. Khattar는 2025년 6월 4일 오후 2시(동부시간) 뉴욕시에서 진행되는 비공식 대화에 참여할 예정입니다.
투자자들은 Jefferies 컨퍼런스 코디네이터를 통해 경영진과의 미팅을 예약할 수 있습니다. 발표는 회사 웹사이트를 통해 라이브 오디오 웹캐스트로 제공되며, 컨퍼런스 종료 후 60일간 다시보기 서비스를 이용할 수 있습니다.
Supernus Pharmaceuticals (NASDAQ : SUPN), une entreprise biopharmaceutique spécialisée dans les maladies du système nerveux central (SNC), a annoncé sa participation à la Conférence mondiale de la santé Jefferies 2025. Le président et CEO Jack A. Khattar participera à une discussion informelle le 4 juin 2025 à 14h00 ET à New York.
Les investisseurs peuvent organiser des réunions avec la direction via le coordinateur de la conférence Jefferies. La présentation sera disponible en webcast audio en direct, accessible depuis le site web de la société, avec une rediffusion disponible pendant 60 jours après la conférence.
Supernus Pharmaceuticals (NASDAQ: SUPN), ein biopharmazeutisches Unternehmen, das sich auf Erkrankungen des zentralen Nervensystems (ZNS) spezialisiert hat, gab seine Teilnahme an der Jefferies Global Healthcare Conference 2025 bekannt. Präsident und CEO Jack A. Khattar wird am 4. Juni 2025 um 14:00 Uhr ET in New York City an einem Gespräch am Kamin teilnehmen.
Investoren können über den Jefferies-Konferenzkoordinator Treffen mit dem Management vereinbaren. Die Präsentation wird als Live-Audio-Webcast auf der Website des Unternehmens verfügbar sein, mit einer Wiederholung, die 60 Tage nach der Konferenz abrufbar ist.
- None.
- None.
ROCKVILLE, Md., May 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 2:00 p.m. ET in New York City.
Investors interested in arranging a meeting with company management during the conference should contact the Jefferies conference coordinator. A live audio webcast of the presentation can be accessed here or by visiting Events & Presentations in the Investor Relations section on the Company's website at www.supernus.com. An archived replay of the webcast will be available for 60 days on the Company's website following the conference.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel CNS product candidates including new potential treatments for epilepsy, depression, and other CNS disorders.
For more information, please visit www.supernus.com.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company’s ability to sustain and increase its profitability; the Company’s ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company’s corporate strategy; the Company’s future financial performance and projected expenditures; the Company’s ability to increase the number of prescriptions written for each of its products and the products of its subsidiaries; the Company’s ability to increase its net revenue from its products and the products of its subsidiaries; the Company’s ability to commercialize its products and the products of its subsidiaries; the Company’s ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company’s product research and development activities, including the timing and progress of the Company’s clinical trials, and projected expenditures; the Company’s ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company’s product candidates; the Company’s ability to protect its intellectual property and the intellectual property of its subsidiaries and operate its business without infringing upon the intellectual property rights of others; the Company’s expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company’s product candidates; the accuracy of the Company’s estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company’s ability to increase its manufacturing capabilities for its products and product candidates; the Company’s projected markets and growth in markets; the Company’s product formulations and patient needs and potential funding sources; the Company’s staffing needs; changes to laws and regulations applicable to our industry, the impact of macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs; and other risk factors set forth from time to time in the Company’s filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.
CONTACTS:
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
(301) 838-2591
or
INVESTOR CONTACT:
Peter Vozzo
ICR Healthcare
(443) 213-0505
peter.vozzo@icrhealthcare.com
FAQ
When is Supernus Pharmaceuticals (SUPN) presenting at the 2025 Jefferies Healthcare Conference?
Who will represent Supernus Pharmaceuticals at the 2025 Jefferies Conference?
How can investors access Supernus Pharmaceuticals' presentation at the Jefferies Conference?
How can investors arrange meetings with Supernus Pharmaceuticals management during the conference?
